Cell‐autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells
- 29 September 2009
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 70 (1) , 90-99
Abstract
BACKGROUND The lethality of prostate cancer is due to the continuous growth of cancer initiating cells (CICs) which are often stimulated by androgen receptor (AR) signaling. However, the underlying molecular mechanism(s) for such AR‐mediated growth stimulation are not fully understood. Such mechanisms may involve cancer cell‐dependent induction of tumor stromal cells to produce paracrine growth factors or could involve cancer cell autonomous autocrine and/or intracellular AR signaling pathways. METHODS We utilized clinical samples, animal models and a series of AR‐positive human prostate cancer cell lines to evaluate AR‐mediated growth stimulation of prostate CICs. RESULTS The present studies document that stromal AR expression is not required for prostate cancer growth, since tumor stroma surrounding AR‐positive human prostate cancer metastases (N = 127) are characteristically AR‐negative. This lack of a requirement for AR expression in tumor stromal cells is also documented by the fact that human AR‐positive prostate cancer cells grow equally well when xenografted in wild‐type versus AR‐null nude mice. AR‐dependent growth stimulation was documented to involve secretion, extracellular binding, and signaling by autocrine growth factors. Orthotopic xenograft animal studies documented that the cellautonomous autocrine growth factors which stimulate prostate CIC growth are not the andromedins secreted by normal prostate stromal cells. Such cell autonomous and extracellular autocrine signaling is necessary but not sufficient for the optimal growth of prostate CICs based upon the response to anti‐androgen plus/or minus preconditioned media. CONCLUSIONS AR‐induced growth stimulation of human prostate CICs requires AR‐dependent intracellular pathways. The identification of such AR‐dependent intracellular pathways offers new leads for the development of effective therapies for prostate cancer. Prostate 70: 90–99, 2010.Keywords
This publication has 38 references indexed in Scilit:
- Stem Cell Characteristics in Prostate Cancer Cell LinesEuropean Urology, 2010
- DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancerEndocrine-Related Cancer, 2009
- Prostate Cancer Cells with Stem Cell Characteristics Reconstitute the Original Human Tumor In vivoCancer Research, 2007
- Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cellsProceedings of the National Academy of Sciences, 2006
- Role of Notch-1 and E-Cadherin in the Differential Response to Calcium in Culturing Normal versus Malignant Prostate CellsCancer Research, 2005
- Role of stromal-epithelial interactions in hormonal responsesArchives of Histology and Cytology, 2004
- Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer modelsThe Prostate, 2003
- Androgen-Stimulated Human Prostate Epithelial Growth Mediated by Stromal-Derived Fibroblast Growth Factor-10.Endocrine Journal, 1999
- CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.1996
- A serum‐free defined medium capable of supporting growth of four established human prostatic carcinoma cell linesThe Prostate, 1994